These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16819390)

  • 1. The trouble with biopsies..
    Baumann U; McKiernan PJ; Kelly DA
    J Pediatr Gastroenterol Nutr; 2006 Jul; 43(1):122. PubMed ID: 16819390
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk factors associated with nonalcoholic fatty liver disease and its relationship with the hepatic histological changes.
    Rodríguez-Hernández H; Gonzalez JL; Márquez-Ramirez MD; Flores-Hernandez M; Rodríguez-Morán M; Guerrero-Romero F
    Eur J Gastroenterol Hepatol; 2008 May; 20(5):399-403. PubMed ID: 18403941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver enzymes, fatty liver and type 2 diabetes.
    Neely D
    Ann Clin Biochem; 2005 May; 42(Pt 3):167-9. PubMed ID: 15949150
    [No Abstract]   [Full Text] [Related]  

  • 4. Apoptosis markers in liver biopsy of nonalcoholic steatohepatitis in pediatric patients.
    Valva P; De Matteo E; Galoppo M; Pedreira A; Giacove G; Lezama C; Marco I; Galoppo MC; Preciado MV
    Hum Pathol; 2008 Dec; 39(12):1816-22. PubMed ID: 18715620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease in type 2 diabetes mellitus.
    Cusi K
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):141-9. PubMed ID: 19262374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive and non-invasive investigations for non-alcoholic steatohepatitis (NASH): the need for biochemical markers.
    Ahmed MH
    Scand J Gastroenterol; 2006 Mar; 41(3):372. PubMed ID: 16497631
    [No Abstract]   [Full Text] [Related]  

  • 7. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects.
    Kotronen A; Juurinen L; Hakkarainen A; Westerbacka J; Cornér A; Bergholm R; Yki-Järvinen H
    Diabetes Care; 2008 Jan; 31(1):165-9. PubMed ID: 17934148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [On the clinical picture of fatty degeneration of the liver and fatty liver].
    Teichmann W; Lindemann A
    Z Gesamte Inn Med; 1967 Sep; 22(17):509-14. PubMed ID: 5591413
    [No Abstract]   [Full Text] [Related]  

  • 9. Is serum alanine transaminase level a reliable marker of histological disease in chronic hepatitis C infection?
    Sanai FM; Benmousa A; Al-Hussaini H; Ashraf S; Alhafi O; Abdo AA; Alameri HF; Akbar HO; Bzeizi KI
    Liver Int; 2008 Aug; 28(7):1011-8. PubMed ID: 18384520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifestyle advice in non-alcoholic fatty liver disease.
    Manco M; Marcellini M; Nobili V
    J Gastroenterol Hepatol; 2007 Apr; 22(4):604-5. PubMed ID: 17376064
    [No Abstract]   [Full Text] [Related]  

  • 11. [When should liver biopsy be considered? Slightly increased ALAT can indicate steatosis--but a histological test is necessary for prognosis].
    Danielsson A
    Lakartidningen; 2004 Sep; 101(38):2862. PubMed ID: 15485168
    [No Abstract]   [Full Text] [Related]  

  • 12. Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragments.
    Yilmaz Y; Kurt R; Kalayci C
    Biomark Med; 2010 Oct; 4(5):743-5. PubMed ID: 20945987
    [No Abstract]   [Full Text] [Related]  

  • 13. [Non-alcoholic fatty liver].
    Zwimpfer J
    Praxis (Bern 1994); 2000 Oct; 89(43):1757-8. PubMed ID: 11103621
    [No Abstract]   [Full Text] [Related]  

  • 14. Allograft steatohepatitis in progressive familial intrahepatic cholestasis type 1 after living donor liver transplantation.
    Miyagawa-Hayashino A; Egawa H; Yorifuji T; Hasegawa M; Haga H; Tsuruyama T; Wen MC; Sumazaki R; Manabe T; Uemoto S
    Liver Transpl; 2009 Jun; 15(6):610-8. PubMed ID: 19479804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum M30 levels: a potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels.
    Yilmaz Y; Ulukaya E; Dolar E
    Hepatology; 2009 Feb; 49(2):697; author reply 697. PubMed ID: 19035337
    [No Abstract]   [Full Text] [Related]  

  • 16. Association of serum gamma-glutamyltransferase and alanine aminotransferase activities with risk of type 2 diabetes mellitus independent of fatty liver.
    Kim CH; Park JY; Lee KU; Kim JH; Kim HK
    Diabetes Metab Res Rev; 2009 Jan; 25(1):64-9. PubMed ID: 19065605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked elevation of serum mitochondrion-derived markers in mild models of non-alcoholic steatohepatitis in rats.
    Murayama H; Ikemoto M; Nagata A
    J Gastroenterol Hepatol; 2009 Feb; 24(2):270-7. PubMed ID: 18823438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biopsy and metabolic findings in blood donors having elevated aminotransferases].
    Hanefeld M; Renger F; Bobach G; Thomas K; Simon H; Haller H
    Z Gesamte Inn Med; 1969 Jan; 24(1):Suppl:127-8. PubMed ID: 5402569
    [No Abstract]   [Full Text] [Related]  

  • 19. Should patients with type 2 diabetes and raised liver enzymes be referred for further evaluation of liver disease?
    Hickman IJ; Russell AJ; Prins JB; Macdonald GA
    Diabetes Res Clin Pract; 2008 Apr; 80(1):e10-2. PubMed ID: 18187226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triglycerides and alanine aminotransferase as screening markers for suspected fatty liver disease in obese children and adolescents.
    Oliveira AM; Oliveira N; Reis JC; Santos MV; Silva AM; Adan L
    Horm Res; 2009; 71(2):83-8. PubMed ID: 19129712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.